NEW YORK – Foundation Medicine announced on Friday its FoundationOne CDx test received approval from the US Food and Drug Administration for use with larotrectinib (Bayer's Vitrakvi) to help identify cancer patients with neurotrophic receptor tyrosine kinase fusions.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.